{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:45:57Z","timestamp":1790880357536,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05579-0","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:32:15Z","timestamp":1781497935000},"page":"18601-18618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging therapeutic strategies in multiple sclerosis: a focus on innovative and targeted approaches"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6361-6586","authenticated-orcid":false,"given":"Husna Irfan","family":"Thalib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9809-872X","authenticated-orcid":false,"given":"Sariya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9644-3370","authenticated-orcid":false,"given":"Sanha","family":"Sideeque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-6140","authenticated-orcid":false,"given":"Taqiyah Zaheerullah","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9121-0088","authenticated-orcid":false,"given":"Aleesha","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-8931","authenticated-orcid":false,"given":"Fatma E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"14","key":"5579_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.21037\/atm.2020.03.131","volume":"8","author":"Z Ahmed","year":"2020","unstructured":"Ahmed Z, Fulton D, Douglas MR (2020) Opicinumab: is it a potential treatment for multiple sclerosis? Ann Transl Med 8(14):892. https:\/\/doi.org\/10.21037\/atm.2020.03.131","journal-title":"Ann Transl Med"},{"issue":"2","key":"5579_CR2","volume":"8","author":"KF Al","year":"2022","unstructured":"Al KF, Craven LJ, Gibbons S, Parvathy SN, Wing AC, Graf C, Parham KA, Kerfoot SM, Wilcox H, Burton JP, Kremenchutzky M (2022) Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: a pilot randomized controlled trial. Mult Scler J Exp Transl Clin 8(2):20552173221086662","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"5579_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2017.08.395","volume":"381","author":"M Araki","year":"2017","unstructured":"Araki M, Nakamura M, Sato W, Takahashi Y, Yamamura T (2017) Potential benefits of the anti-IL-6 receptor antibody tocilizumab in multiple sclerosis patients with high plasmablast frequency. J Neurol Sci 381:131","journal-title":"J Neurol Sci"},{"issue":"14","key":"5579_CR4","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A et al (2020) Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology 95(14):e1999\u2013e2008. https:\/\/doi.org\/10.1212\/WNL.0000000000010380","journal-title":"Neurology"},{"key":"5579_CR5","doi-asserted-by":"publisher","unstructured":"Bar-Or A, Traboulsee A, Kister I et al (2023) Fenebrutinib in relapsing multiple sclerosis: primary results from the phase 2 FENopta study. https:\/\/doi.org\/10.55788\/002fd847","DOI":"10.55788\/002fd847"},{"issue":"4","key":"5579_CR6","volume":"118","author":"J Bourque","year":"2021","unstructured":"Bourque J, Hawiger D (2021) Current and future immunotherapies for multiple sclerosis. Missouri Med 118(4):334339","journal-title":"Missouri Med"},{"issue":"11","key":"5579_CR7","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1007\/s00415-021-10545-2","volume":"268","author":"D Centonze","year":"2021","unstructured":"Centonze D, Rocca MA, Gasperini C et al (2021) Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 268(11):3961\u20133968. https:\/\/doi.org\/10.1007\/s00415-021-10545-2","journal-title":"J Neurol"},{"key":"5579_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210142","author":"JJ Cerqueira","year":"2025","unstructured":"Cerqueira JJ, Berthele A, Cree BAC et al (2025) Long-term treatment with ocrelizumab in patients with early-stage relapsing MS. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000210142","journal-title":"Neurology"},{"issue":"6","key":"5579_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/brainsci10060338","volume":"10","author":"M Chountoulesi","year":"2020","unstructured":"Chountoulesi M, Demetzos C (2020) Promising nanotechnology approaches in treatment of autoimmune diseases of central nervous system. Brain Sci 10(6):338. https:\/\/doi.org\/10.3390\/brainsci10060338","journal-title":"Brain Sci"},{"issue":"2","key":"5579_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","volume":"81","author":"J Chun","year":"2021","unstructured":"Chun J, Giovannoni G, Hunter SF (2021) Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs 81(2):207\u2013231. https:\/\/doi.org\/10.1007\/s40265-020-01431-8","journal-title":"Drugs"},{"issue":"4","key":"5579_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acn3.52017","volume":"11","author":"PK Coyle","year":"2024","unstructured":"Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE (2024) Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review. Ann Clin Transl Neurol 11(4):842\u2013855. https:\/\/doi.org\/10.1002\/acn3.52017","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"5579_CR12","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1007\/s12325-021-01761-3","volume":"38","author":"PK Coyle","year":"2021","unstructured":"Coyle PK, Gocke A, Vignos M, Newsome SD (2021) Vaccine considerations for multiple sclerosis in the COVID19 era. Adv Ther 38(7):3550\u20133588. https:\/\/doi.org\/10.1007\/s12325-021-01761-3","journal-title":"Adv Ther"},{"issue":"3","key":"5579_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","volume":"35","author":"BAC Cree","year":"2022","unstructured":"Cree BAC, Hartung HP, Barnett MH (2022) New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol 35(3):262\u2013270. https:\/\/doi.org\/10.1097\/WCO.0000000000001063","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"5579_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","volume":"81","author":"AH Cross","year":"2024","unstructured":"Cross AH, Gelfand JM, Thebault S, Bennett JL, Von B\u00fcdingen HC, Cameron B, Carruthers R, Edwards K, Fallis R, Gerstein R, Giacomini PS (2024) Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol 81(4):373\u2013383","journal-title":"JAMA Neurol"},{"key":"5579_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624685","volume":"12","author":"J Derdelinckx","year":"2021","unstructured":"Derdelinckx J, Cras P, Berneman ZN, Cools N (2021) Antigen-specific treatment modalities in MS: the past, the present, and the future. Front Immunol 12:624685. https:\/\/doi.org\/10.3389\/fimmu.2021.624685","journal-title":"Front Immunol"},{"key":"5579_CR16","doi-asserted-by":"publisher","unstructured":"Deva R, Rajendran P (2022) Recent advances in the management of multiple sclerosis. Int J Basic Clin Pharmacol 11(5). https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20221826","DOI":"10.18203\/2319-2003.ijbcp20221826"},{"issue":"6","key":"5579_CR17","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00394-024-03428-5","volume":"63","author":"N Dolatkhah","year":"2024","unstructured":"Dolatkhah N, Jafari A, Eslamian F, Toopchizadeh V, Saleh P, Hashemian M (2024) Saccharomyces boulardii improves clinical and paraclinical indices in overweight\/obese knee osteoarthritis patients: a randomized triple-blind placebo-controlled trial. Eur J Nutr 63(6):2291\u20132305","journal-title":"Eur J Nutr"},{"key":"5579_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915218","volume":"13","author":"HX Du","year":"2022","unstructured":"Du HX, Yue SY, Niu D, Liu C, Zhang LG, Chen J, Chen Y, Guan Y, Hua XL, Li C, Chen XG (2022) Gut microflora modulates Th17\/Treg cell differentiation in experimental autoimmune prostatitis via the short-chain fatty acid propionate. Front Immunol 13:915218","journal-title":"Front Immunol"},{"issue":"48","key":"5579_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696","volume":"1","author":"PM Elsbernd","year":"2021","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM (2021) Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Multiple Sclerosis and Related Disorders 1(48):102696","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"5579_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40478-023-01614-w.PMID:37438842;PMCID:PMC10337138","volume":"11","author":"KS Evonuk","year":"2023","unstructured":"Evonuk KS, Wang S, Mattie J, Cracchiolo CJ, Mager R, Feren\u010di\u0107 \u017d, Sprague E, Carrier B, Schofield K, Martinez E, Stewart Z, Petrosino T, Johnson GA, Yusuf I, Plaisted W, Naiman Z, Delp T, Carter L, Maru\u0161i\u0107 S (2023) Bruton\u2019s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination. Acta Neuropathol Commun 11(1):115. https:\/\/doi.org\/10.1186\/s40478-023-01614-w.PMID:37438842;PMCID:PMC10337138","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"5579_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese MA, Heesen C, Kr\u00f6ger N (2024) CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5(6):550-558.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002","journal-title":"Med"},{"issue":"4","key":"5579_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/life11040327","volume":"11","author":"N Gacem","year":"2021","unstructured":"Gacem N, Nait-Oumesmar B (2021) Oligodendrocyte development and regenerative therapeutics in multiple sclerosis. Life 11(4):327. https:\/\/doi.org\/10.3390\/life11040327","journal-title":"Life"},{"key":"5579_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221078825","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A et al (2022) Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: ASCLEPIOS I and II. Mult Scler. https:\/\/doi.org\/10.1177\/13524585221078825","journal-title":"Mult Scler"},{"key":"5579_CR24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1789394","author":"M Gerhardt","year":"2024","unstructured":"Gerhardt M, Bonato GD, dos Passos GR, Becker J (2024) Combination of secukinumab and natalizumab in the treatment of a patient with psoriatic arthritis and multiple sclerosis. Arq Neuropsiquiatr. https:\/\/doi.org\/10.1055\/s-0044-1789394","journal-title":"Arq Neuropsiquiatr"},{"issue":"10","key":"5579_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413953122","volume":"122","author":"S Ghimire","year":"2025","unstructured":"Ghimire S, Lehman PC, Aguilar Meza LS, Shahi SK, Hoang J, Olalde H, Paullus M, Cherwin C, Wang K, Gill C, Cho T (2025) Specific microbial ratio in the gut microbiome is associated with multiple sclerosis. Proc Natl Acad Sci 122(10):e2413953122","journal-title":"Proc Natl Acad Sci"},{"key":"5579_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00539","author":"DS Goodin","year":"2025","unstructured":"Goodin DS (2025) The epidemiology, pathology and pathogenesis of MS: therapeutic implications. Neurotherapeutics. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00539","journal-title":"Neurotherapeutics"},{"issue":"5","key":"5579_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052589","volume":"25","author":"C Grunwald","year":"2024","unstructured":"Grunwald C, Kr\u0119towska-Grunwald A, Adamska-Patruno E, Kochanowicz J, Ku\u0142akowska A, Chor\u0105\u017cy M (2024) The role of selected interleukins in the development and progression of multiple sclerosis\u2014a systematic review. Int J Mol Sci 25(5):2589","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5579_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00415-021-10663-x","volume":"269","author":"S Guerrieri","year":"2022","unstructured":"Guerrieri S, Lazzarin S, Zanetta C et al (2022) Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol 269(1):39\u201343. https:\/\/doi.org\/10.1007\/s00415-021-10663-x","journal-title":"J Neurol"},{"issue":"1","key":"5579_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1713648","volume":"12","author":"KJM Hanf","year":"2020","unstructured":"Hanf KJM, Arndt JW, Liu Y, Gong BJ, Rushe M, Sopko R et al (2020) Functional activity of antiLINGO1 antibody opicinumab requires target engagement at a secondary binding site. Mabs 12(1):1713648. https:\/\/doi.org\/10.1080\/19420862.2020.1713648","journal-title":"Mabs"},{"issue":"3","key":"5579_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"3","key":"5579_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-020-0311-9","volume":"16","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of progressive multiple sclerosis: current approaches and unmet needs. Nat Rev Neurol 16(3):135\u2013146. https:\/\/doi.org\/10.1038\/s41582-020-0311-9","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5579_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12883-025-04145-0","volume":"25","author":"J Itorralba","year":"2025","unstructured":"Itorralba J, Brand-Arzamendi K, Saab G, Muccilli A, Schneider R (2025) Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis. BMC Neurol 25(1):136","journal-title":"BMC Neurol"},{"issue":"1","key":"5579_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/vaccines8010050","volume":"8","author":"D Jakimovski","year":"2020","unstructured":"Jakimovski D, WeinstockGuttman B, Ramanathan M, Dwyer MG, Zivadinov R (2020) Infections, vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines 8(1):50. https:\/\/doi.org\/10.3390\/vaccines8010050","journal-title":"Vaccines"},{"issue":"13","key":"5579_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.966766","volume":"27","author":"L Jiao","year":"2022","unstructured":"Jiao L, Guo S (2022) Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol 27(13):966766","journal-title":"Front Immunol"},{"issue":"6","key":"5579_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s41669-024-00510-w","volume":"8","author":"A Keenan","year":"2024","unstructured":"Keenan A, Whichello C, Le HH, Kern DM, Fernandez GS, Turner V, Das A, Quaife M, Ross AP (2024) Clinicians\u2019 preferences for sphingosine-1-phosphate receptor modulators in multiple sclerosis based on clinical management considerations: a choice experiment. Pharmacoecon Open 8(6):857\u2013867. https:\/\/doi.org\/10.1007\/s41669-024-00510-w","journal-title":"Pharmacoecon Open"},{"key":"5579_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108432","volume":"246","author":"Y Kihara","year":"2023","unstructured":"Kihara Y, Chun J (2023) Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis. Pharmacol Ther 246:108432. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108432","journal-title":"Pharmacol Ther"},{"issue":"14","key":"5579_CR37","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.3390\/cells11142165","volume":"11","author":"FF Konen","year":"2022","unstructured":"Konen FF, Schwenkenbecher P, Jendretzky KF, Gingele S, Grote-Levi L, M\u00f6hn N, S\u00fchs KW, Eiz-Vesper B, Maecker-Kolhoff B, Trebst C, Skripuletz T, H\u00fcmmert MW (2022) Stem cell therapy in neuroimmunological diseases and its potential neuroimmunological complications. Cells 11(14):2165. https:\/\/doi.org\/10.3390\/cells11142165","journal-title":"Cells"},{"issue":"6","key":"5579_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41582-024-00992-3","volume":"20","author":"T Korn","year":"2024","unstructured":"Korn T, Menke T, Schreiner B, Hemmer B (2024) B cell-directed CAR T cells as a novel treatment option in neuroimmunological and neurodegenerative diseases of the CNS. Nat Rev Neurol 20(6):351\u2013365. https:\/\/doi.org\/10.1038\/s41582-024-00992-3","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5579_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-024-03267-5","volume":"21","author":"J Langlois","year":"2024","unstructured":"Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C, DeGeer J, Sudharshan TJJ, Yong VW, Shen YA, Harp C, Collin L, Keaney J (2024) Fenebrutinib, a Bruton\u2019s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation 21(1):276. https:\/\/doi.org\/10.1186\/s12974-024-03267-5","journal-title":"J Neuroinflammation"},{"issue":"136","key":"5579_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111211","volume":"1","author":"E Madill","year":"2025","unstructured":"Madill E, Galetta K, Opeyemi O, Pua DK, Gandelman S, Chitnis T, Bhattacharyya S (2025) Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: a multi-center exploratory study. J Clin Neurosci 1(136):111211","journal-title":"J Clin Neurosci"},{"key":"5579_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01616412.2025.2507756","volume":"20","author":"H Makhzoum","year":"2025","unstructured":"Makhzoum H, El Majzoub R, Ismail A, Kassem M, Kotaich J, Chahine B (2025) Interventions promoting remyelination in multiple sclerosis: a systematic review of clinical trials. Neurol Res 20:1\u201318. https:\/\/doi.org\/10.1080\/01616412.2025.2507756","journal-title":"Neurol Res"},{"issue":"6","key":"5579_CR42","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/imj.70023","volume":"55","author":"T Montague","year":"2025","unstructured":"Montague T, Drummond J, Ng K, Parratt J (2025) Advancements in multiple sclerosis. Intern Med J 55(6):895\u2013904. https:\/\/doi.org\/10.1111\/imj.70023","journal-title":"Intern Med J"},{"issue":"11","key":"5579_CR43","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"X Montalban","year":"2024","unstructured":"Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D (2024) Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol 23(11):1119\u20131132. https:\/\/doi.org\/10.1016\/S1474-4422(24)00328-4","journal-title":"Lancet Neurol"},{"issue":"4","key":"5579_CR44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40120-022-00389-x","volume":"11","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh F, Pirahesh K, Rafiei N, Afrashteh F, Ahmadabad MA, Zabeti A, Mirmosayyeb O (2022) Autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol Ther 11(4):1553\u20131569. https:\/\/doi.org\/10.1007\/s40120-022-00389-x","journal-title":"Neurol Ther"},{"issue":"1","key":"5579_CR45","doi-asserted-by":"publisher","first-page":"12545","DOI":"10.1038\/s41598-024-62726-4","volume":"14","author":"AA Nawar","year":"2024","unstructured":"Nawar AA, Farid AM, Wally R, Tharwat EK, Sameh A, Elkaramany Y, Asla MM, Kamel WA (2024) Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 14(1):12545. https:\/\/doi.org\/10.1038\/s41598-024-62726-4","journal-title":"Sci Rep"},{"issue":"16","key":"5579_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168866","volume":"22","author":"D Nuzzo","year":"2021","unstructured":"Nuzzo D, Picone P (2021) Multiple sclerosis: focus on extracellular and artificial vesicles, nanoparticles as potential therapeutic approaches. Int J Mol Sci 22(16):8866. https:\/\/doi.org\/10.3390\/ijms22168866","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5579_CR47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/WCO.0000000000000929","volume":"34","author":"S Otero-Romero","year":"2021","unstructured":"Otero-Romero S, Ascherio A, Lebrun-Fr\u00e9nay C (2021) Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 34(3):322\u2013328. https:\/\/doi.org\/10.1097\/WCO.0000000000000929","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"5579_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s11671-024-04135-0","volume":"19","author":"A Panghal","year":"2024","unstructured":"Panghal A, Flora SJS (2024) Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis. Discov Nano 19(1):171. https:\/\/doi.org\/10.1186\/s11671-024-04135-0","journal-title":"Discov Nano"},{"issue":"11","key":"5579_CR49","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R (2014) Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler J 20(11):1541\u20131544","journal-title":"Mult Scler J"},{"issue":"6","key":"5579_CR50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.13215","volume":"289","author":"F Piehl","year":"2021","unstructured":"Piehl F (2021) Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med 289(6):771\u2013791. https:\/\/doi.org\/10.1111\/joim.13215","journal-title":"J Intern Med"},{"key":"5579_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, Di Filippo M, Tur C, Montalban X, Amato MP (2024) Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur 44:100977. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"5579_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.62347\/QHVI3317","volume":"14","author":"D Rafieezadeh","year":"2025","unstructured":"Rafieezadeh D, Sabeti G, Khalaji A, Mohammadi H (2025) Advances in nanotechnology for targeted drug delivery in neurodegenerative diseases. Am J Neurodegener Dis 14(2):51\u201357. https:\/\/doi.org\/10.62347\/QHVI3317","journal-title":"Am J Neurodegener Dis"},{"issue":"1","key":"5579_CR53","doi-asserted-by":"publisher","DOI":"10.4103\/jehp.jehp_521_22","volume":"12","author":"H Rahimi","year":"2023","unstructured":"Rahimi H, Pirmoradi M, Lavasani FF, Farahani H (2023) The effectiveness of group intervention focused on intolerance of uncertainty on psychological distress and quality of life in multiple sclerosis patients. J Educ Health Promot 12(1):29","journal-title":"J Educ Health Promot"},{"issue":"2","key":"5579_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/1028415X.2020.1758887","volume":"25","author":"M Rahimlou","year":"2022","unstructured":"Rahimlou M, Hosseini SA, Majdinasab N, Haghighizadeh MH, Husain D (2022) Effects of long-term administration of multi-strain probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Nutr Neurosci 25(2):411\u2013422","journal-title":"Nutr Neurosci"},{"issue":"6","key":"5579_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","volume":"20","author":"S Reyes","year":"2020","unstructured":"Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C et al (2020) Protecting people with multiple sclerosis through vaccination. Pract Neurol 20(6):435\u2013445. https:\/\/doi.org\/10.1136\/practneurol-2020-002527","journal-title":"Pract Neurol"},{"key":"5579_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.989471","volume":"10","author":"MM Rhaman","year":"2022","unstructured":"Rhaman MM, Islam MR, Akash S, Mim M, Noor Alam M, Nepovimova E, Valis M, Kuca K, Sharma R (2022) Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: at a glance. Front Cell Dev Biol 10:989471. https:\/\/doi.org\/10.3389\/fcell.2022.989471","journal-title":"Front Cell Dev Biol"},{"key":"5579_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2022-anzan.26","author":"I Roos","year":"2022","unstructured":"Roos I, Sharmin S, Lechner-Scott J et al (2022) Comparison of the effectiveness of ocrelizumab vs interferon \u03b2, fingolimod and natalizumab on relapses in RRMS. BMJ Neurol Open. https:\/\/doi.org\/10.1136\/bmjno-2022-anzan.26","journal-title":"BMJ Neurol Open"},{"issue":"6","key":"5579_CR58","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1053\/j.gastro.2021.01.010","volume":"160","author":"S Saha","year":"2021","unstructured":"Saha S, Mara K, Pardi DS, Khanna S (2021) Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection. Gastroenterology 160(6):1961\u20131969","journal-title":"Gastroenterology"},{"issue":"3","key":"5579_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1444","volume":"12","author":"C Smith","year":"2023","unstructured":"Smith C, Khanna R (2023) Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis. Clin Transl Immunol 12(3):e1444. https:\/\/doi.org\/10.1002\/cti2.1444","journal-title":"Clin Transl Immunol"},{"key":"5579_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03978-3","author":"S Soni","year":"2025","unstructured":"Soni S, Kaur G (2025) Emerging therapeutic application of clemastine: a review of recent patents updates. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-03978-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"5579_CR61","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2174\/1381612827666210701152934","volume":"28","author":"A Steinmaurer","year":"2022","unstructured":"Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J (2022) Bruton\u2019s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. Curr Pharm des 28(6):437\u2013444. https:\/\/doi.org\/10.2174\/1381612827666210701152934","journal-title":"Curr Pharm des"},{"issue":"8","key":"5579_CR62","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/13543784.2021.1942840","volume":"30","author":"R Sutiwisesak","year":"2021","unstructured":"Sutiwisesak R, Burns TC, Rodriguez M, Warrington AE (2021) Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opin Investig Drugs 30(8):857\u2013876. https:\/\/doi.org\/10.1080\/13543784.2021.1942840","journal-title":"Expert Opin Investig Drugs"},{"key":"5579_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104551","volume":"71","author":"E Swallow","year":"2023","unstructured":"Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K (2023) Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: a matching-adjusted indirect comparison. Mult Scler Relat Disord 71:104551. https:\/\/doi.org\/10.1016\/j.msard.2023.104551","journal-title":"Mult Scler Relat Disord"},{"key":"5579_CR64","doi-asserted-by":"publisher","unstructured":"Tauseef A, Hayee S (2021) Multiple sclerosis: a neurological disorder. THE THERAPIST: J Ther Rehabil Sci pp 02\u20133. Available from: https:\/\/doi.org\/10.54393\/tt.v1i1.1","DOI":"10.54393\/tt.v1i1.1"},{"key":"5579_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","author":"I Tramacere","year":"2015","unstructured":"Tramacere I, Del Giovane C, Salanti G et al (2015) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011381.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5579_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.13005\/bpj\/2349","volume":"15","author":"PB Vani","year":"2022","unstructured":"Vani PB, Chitra V (2022) The role of the proinflammatory and anti-inflammatory cytokines in multiple sclerosis. Biomed Pharmacol J 15(1):137\u2013146","journal-title":"Biomedical and Pharmacology Journal"},{"key":"5579_CR67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11882-023-01000-1","volume":"23","author":"ES Vasileiou","year":"2023","unstructured":"Vasileiou ES, Fitzgerald KC (2023) Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches. Curr Allergy Asthma Rep 23:481\u2013496. https:\/\/doi.org\/10.1007\/s11882-023-01000-1","journal-title":"Curr Allergy Asthma Rep"},{"key":"5579_CR68","doi-asserted-by":"publisher","unstructured":"Yamazaki R, Ohno N (2025) The potential of repurposing clemastine to promote remyelination. Front Cell Neurosci 19. https:\/\/doi.org\/10.3389\/fncel.2025.1582902","DOI":"10.3389\/fncel.2025.1582902"},{"key":"5579_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12360-x","author":"A Zangh\u00ec","year":"2024","unstructured":"Zangh\u00ec A, Borriello G, Bonavita S et al (2024) Ocrelizumab and ofatumumab comparison: an Italian Real-World propensity Score Matched Study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12360-x","journal-title":"J Neurol"},{"issue":"19","key":"5579_CR70","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","volume":"185","author":"X Zhou","year":"2022","unstructured":"Zhou X, Baumann R, Gao X, Mendoza M, Singh S, Sand IK, Xia Z, Cox LM, Chitnis T, Yoon H, Moles L (2022) Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell 185(19):3467\u20133486","journal-title":"Cell"},{"key":"5579_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330104","author":"C Zhu","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I et al (2022) Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2022-330104","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05579-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:14:29Z","timestamp":1789978469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5579"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05579-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a literature review and does not involve any studies with human or animal subjects performed by the author.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that no artificial intelligence tools or paper mill services were used in the preparation, writing, or submission of this manuscript. AI was used for figure refinement; all scientific information was cross checked by authors to confirm accuracy.","order":5,"name":"Ethics","label":"Use of artificial intelligence and paper mills","group":{"name":"EthicsHeading","label":"Declarations"}}]}}